261 related articles for article (PubMed ID: 10147354)
1. Ranitidine: a pharmacoeconomic evaluation of its use in acid-related disorders.
Frampton JE; McTavish D
Pharmacoeconomics; 1994 Jul; 6(1):57-89. PubMed ID: 10147354
[TBL] [Abstract][Full Text] [Related]
2. Omeprazole: a pharmacoeconomic evaluation of its use in duodenal ulcer and reflux oesophagitis.
Barradell LB; McTavish D
Pharmacoeconomics; 1993 Jun; 3(6):482-510. PubMed ID: 10146883
[TBL] [Abstract][Full Text] [Related]
3. Economic evaluation in gastrointestinal disease.
Jönsson B; Karlsson G
Scand J Gastroenterol Suppl; 1996; 220():44-51. PubMed ID: 8898435
[TBL] [Abstract][Full Text] [Related]
4. Omeprazole. An update of its pharmacology and therapeutic use in acid-related disorders.
Wilde MI; McTavish D
Drugs; 1994 Jul; 48(1):91-132. PubMed ID: 7525198
[TBL] [Abstract][Full Text] [Related]
5. Decision analysis of histamine H2-receptor antagonist maintenance therapy versus Helicobacter pylori eradication therapy: a randomised controlled trial in patients with continuing pain after duodenal ulcer.
Tavakoli M; Prach AT; Malek M; Hopwood D; Senior BW; Murray FE
Pharmacoeconomics; 1999 Oct; 16(4):355-65. PubMed ID: 10623364
[TBL] [Abstract][Full Text] [Related]
6. Rabeprazole: an update of its use in acid-related disorders.
Carswell CI; Goa KL
Drugs; 2001; 61(15):2327-56. PubMed ID: 11772142
[TBL] [Abstract][Full Text] [Related]
7. H2-antagonist maintenance therapy versus Helicobacter pylori eradication in patients with chronic duodenal ulcer disease: a prospective study.
Prach AT; Malek M; Tavakoli M; Hopwood D; Senior BW; Murray FE
Aliment Pharmacol Ther; 1998 Sep; 12(9):873-80. PubMed ID: 9768530
[TBL] [Abstract][Full Text] [Related]
8. Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding.
Leontiadis GI; Sreedharan A; Dorward S; Barton P; Delaney B; Howden CW; Orhewere M; Gisbert J; Sharma VK; Rostom A; Moayyedi P; Forman D
Health Technol Assess; 2007 Dec; 11(51):iii-iv, 1-164. PubMed ID: 18021578
[TBL] [Abstract][Full Text] [Related]
9. Relapse prevention in reflux oesophagitis with regard to Helicobacter pylori status: a double-blind, randomized, multicentre trial to compare the efficacy of pantoprazole versus ranitidine.
Adamek RJ; Behrendt J; Wenzel C
Eur J Gastroenterol Hepatol; 2001 Jul; 13(7):811-7. PubMed ID: 11474311
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of Helicobacter pylori eradication therapy in duodenal ulcer disease.
Jönsson B
Scand J Gastroenterol Suppl; 1996; 215():90-5. PubMed ID: 8722390
[TBL] [Abstract][Full Text] [Related]
11. Pantoprazole. A review of its pharmacological properties and therapeutic use in acid-related disorders.
Fitton A; Wiseman L
Drugs; 1996 Mar; 51(3):460-82. PubMed ID: 8882382
[TBL] [Abstract][Full Text] [Related]
12. Cost savings in duodenal ulcer therapy through Helicobacter pylori eradication compared with conventional therapies: results of a randomized, double-blind, multicenter trial. Gastrointestinal Utilization Trial Study Group.
Sonnenberg A; Schwartz JS; Cutler AF; Vakil N; Bloom BS
Arch Intern Med; 1998 Apr; 158(8):852-60. PubMed ID: 9570170
[TBL] [Abstract][Full Text] [Related]
13. Omeprazole. An updated review of its pharmacology and therapeutic use in acid-related disorders.
McTavish D; Buckley MM; Heel RC
Drugs; 1991 Jul; 42(1):138-70. PubMed ID: 1718683
[TBL] [Abstract][Full Text] [Related]
14. Omeprazole and H2-receptor antagonists in the acute treatment of duodenal ulcer, gastric ulcer and reflux oesophagitis: a meta-analysis.
Eriksson S; Långström G; Rikner L; Carlsson R; Naesdal J
Eur J Gastroenterol Hepatol; 1995 May; 7(5):467-75. PubMed ID: 7614110
[TBL] [Abstract][Full Text] [Related]
15. Triple therapy eradicated H. pylori equally in patients pretreated with omeprazole or ranitidine. A 12-month follow-up.
Archimandritis A; Balatsos V; Delis V; Mentis A; Kastanas K; Scandalis N
J Clin Gastroenterol; 1995 Jan; 20(1):12-6. PubMed ID: 7884169
[TBL] [Abstract][Full Text] [Related]
16. Effect of triple therapy or amoxycillin plus omeprazole or amoxycillin plus tinidazole plus omeprazole on duodenal ulcer healing, eradication of Helicobacter pylori, and prevention of ulcer relapse over a 1-year follow-up period: a prospective, randomized, controlled study.
Saberi-Firoozi M; Massarrat S; Zare S; Fattahi M; Javan A; Etaati H; Dehbashi N
Am J Gastroenterol; 1995 Sep; 90(9):1419-23. PubMed ID: 7661161
[TBL] [Abstract][Full Text] [Related]
17. Omeprazole. A review of its use in Helicobacter pylori infection, gastro-oesophageal reflux disease and peptic ulcers induced by nonsteroidal anti-inflammatory drugs.
Langtry HD; Wilde MI
Drugs; 1998 Sep; 56(3):447-86. PubMed ID: 9777317
[TBL] [Abstract][Full Text] [Related]
18. Pharmacoeconomic comparison of Helicobacter pylori eradication regimens.
Sancar M; Izzettin FV; Apikoglu-Rabus S; Besisik F; Tozun N; Dulger G
Pharm World Sci; 2006 Aug; 28(4):207-14. PubMed ID: 17066247
[TBL] [Abstract][Full Text] [Related]
19. Duodenal ulcer and gastroesophageal reflux disease today: long-term therapy--a sideways glance.
Bardhan KD
Yale J Biol Med; 1996; 69(3):211-24. PubMed ID: 9165690
[TBL] [Abstract][Full Text] [Related]
20. Cost effectiveness of alternative Helicobacter pylori eradication strategies in the management of duodenal ulcer.
O'Brien B; Goeree R; Hunt R; Wilkinson J; Levine M; William A
Can J Gastroenterol; 1997; 11(4):323-31. PubMed ID: 9218858
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
